Up to 8% of patients receiving<unk>  are at risk to develop<unk>  antibodies, but only 1–5% on<unk>  will progress to develop<unk>  with<unk>  and subsequently one-third of them may suffer from arterial and/or venous thrombosis. After vascular surgery, 34% of patients receiving<unk>  developed<unk>  antibodies without clinical symptoms. The exact number of cases of<unk>  in the general population is unknown. What is known is that women receiving<unk>  after a recent surgical procedure, particularly cardiothoracic surgery, have a higher risk, while the risk is very low in women just before and after giving birth. Some studies have shown that<unk>  is less common in those receiving low molecular weight<unk> .
Heparin-induced thrombocytopenia
Sticky platelet syndrome
Venom-induced consumption coagulopathy
Pseudo gray platelet syndrome
Drug-induced thrombocytopenic purpura
Gray platelet syndrome
Disseminated intravascular coagulation
Immune thrombocytopenic purpura